A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

Also called NCT03901729

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 482 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03901729
  • EudraCT 2018-004059-18
Other papers using this trial's data
  • A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial European journal of heart failure, 2025-11 DOI, PubMed 40788619

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Bulgaria, Greece, Hungary, Israel, Italy, Poland, Portugal, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03901729. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-29 (actual); primary completion 2021-04-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
Acronym
AVANTI
Condition
Heart Failure (HF)
Intervention (Drug)
BAY 1753011
Intervention (Other)
Placebo BAY 1753011
Intervention (Drug)
Furosemide
Intervention (Other)
Placebo Furosemide
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03901729
Content hash
c4bb11ed39b3b10247768a4db338699b6c9bce3a338fefdb9809b96c00833163